Integrated Wealth Concepts LLC Grows Stock Holdings in Colgate-Palmolive (NYSE:CL)

Integrated Wealth Concepts LLC grew its holdings in shares of Colgate-Palmolive (NYSE:CL - Free Report) by 158.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,269 shares of the company's stock after buying an additional 10,584 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Colgate-Palmolive were worth $1,570,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. grew its stake in Colgate-Palmolive by 66.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 942,870 shares of the company's stock worth $85,716,000 after buying an additional 377,900 shares during the period. T. Rowe Price Investment Management Inc. purchased a new position in shares of Colgate-Palmolive in the fourth quarter valued at $456,000. Pinebridge Investments L.P. boosted its stake in shares of Colgate-Palmolive by 143.1% in the fourth quarter. Pinebridge Investments L.P. now owns 429,295 shares of the company's stock valued at $39,027,000 after purchasing an additional 252,684 shares during the period. Alta Advisers Ltd boosted its stake in shares of Colgate-Palmolive by 20.4% in the fourth quarter. Alta Advisers Ltd now owns 2,770 shares of the company's stock valued at $252,000 after purchasing an additional 470 shares during the period. Finally, J. Safra Sarasin Holding AG boosted its stake in shares of Colgate-Palmolive by 3.5% in the fourth quarter. J. Safra Sarasin Holding AG now owns 832,049 shares of the company's stock valued at $75,641,000 after purchasing an additional 27,926 shares during the period. 80.41% of the stock is currently owned by hedge funds and other institutional investors.

Colgate-Palmolive Stock Down 3.1 %

Shares of NYSE:CL opened at $90.99 on Tuesday. The stock has a market capitalization of $73.80 billion, a price-to-earnings ratio of 25.85, a price-to-earnings-growth ratio of 4.20 and a beta of 0.40. Colgate-Palmolive has a 1-year low of $85.32 and a 1-year high of $109.30. The company's fifty day moving average is $92.14 and its two-hundred day moving average is $92.05. The company has a debt-to-equity ratio of 13.40, a quick ratio of 0.58 and a current ratio of 0.92.

Colgate-Palmolive (NYSE:CL - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.86 by $0.05. Colgate-Palmolive had a net margin of 14.38% and a return on equity of 477.77%. The business had revenue of $4.91 billion for the quarter, compared to analysts' expectations of $4.92 billion. During the same quarter last year, the company earned $0.86 EPS. The company's revenue for the quarter was down 3.0% compared to the same quarter last year. Equities analysts anticipate that Colgate-Palmolive will post 3.75 EPS for the current year.

Colgate-Palmolive announced that its board has authorized a share buyback program on Thursday, March 20th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

Colgate-Palmolive Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Thursday, April 17th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.29%. The ex-dividend date is Thursday, April 17th. This is a boost from Colgate-Palmolive's previous quarterly dividend of $0.50. Colgate-Palmolive's dividend payout ratio (DPR) is 59.09%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on CL shares. Citigroup upped their target price on shares of Colgate-Palmolive from $103.00 to $108.00 and gave the company a "buy" rating in a research note on Monday. Raymond James restated an "outperform" rating and issued a $105.00 target price (down from $110.00) on shares of Colgate-Palmolive in a research note on Monday, February 3rd. Royal Bank of Canada restated a "sector perform" rating and issued a $101.00 target price on shares of Colgate-Palmolive in a research note on Wednesday, January 29th. Stifel Nicolaus cut their price target on shares of Colgate-Palmolive from $95.00 to $93.00 and set a "hold" rating on the stock in a report on Monday, February 3rd. Finally, Barclays cut their price target on shares of Colgate-Palmolive from $89.00 to $86.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Colgate-Palmolive presently has an average rating of "Hold" and a consensus price target of $102.39.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.